Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis.

Its DROPZYLLA™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. Combined with our microfluidic high throughput single cell-based functional screening system this leads to entirely new possibilities in immune repertoire analysis and antibody discovery.

The business strategy of Memo Therapeutics is the discovery of therapeutic antibody candidates and target discovery for antibody and vaccine development. DROPZYLLA™ is deployed in proprietary antibody discovery programs and is made available in collaborations e.g. for screening of CAR-T; TCR-T or bi-specific antibodies.

Federal Office of Public Health (FOPH) Switzerland

Schroder Adveq

Zürcher Kantonal Bank

Verve Ventures

Redalpine

Bernina BioInvest

Jaquet Partners

Swisscanto Private Equity

Adjuvant Capital

Fresenius Medical Care

Vesalius Biocapital Partners

GF Group Holding

Memo Therapeutics AG

“AntiBKV has the potential to be a best- and first-in-class antibody for the treatment of BKV infection in kidney transplant recipients. With 50,000 kidney transplant procedures carried out in the US and Europe alone, AntiBKV addresses a large and rapidly growing market, with an estimated size well beyond USD 1 billion,” said Karsten Fischer, Chief Executive Officer of Memo Therapeutics AG.

#clinicaltrials #phase1 

https://lnkd.in/erjNXiGc

Memo Therapeutics AG is a late-stage biotech company developing therapeutic antibodies for virus infections and cancer. Their lead program, AntiBKV, is a neutralizing antibody for treating BK virus infection in kidney transplant recipients. They also have a pipeline of antibodies targeting infectious diseases and immuno-oncology. Their technology platform enables high-throughput screening and identification of potent antibodies.

COM:MEMO-THERAPEUTICS

Memo Therapeutics AG

Filings Not Available